Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 9/20 | 0.57 |
| ▸ | P2RX3 | P56373 | 7/20 | 0.47 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.46 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18731913 | 0.88 | CNR2 (0.48) | CNR2P2RX3KCNH2KDM4ETLR8 | |
| SCHEMBL3617884 | 0.85 | KDM4E (0.64) | CNR2KCNH2KDM4ERAD52 | |
| SCHEMBL13035832 | 0.81 | TNF (0.57) | CNR2KDM4E | |
| SCHEMBL16806056 | 0.81 | CYP1A2 (0.53) | CNR2KCNH2 | |
| SCHEMBL2950054 | 0.79 | CNR2 (0.65) | CNR2KCNH2KDM4E | |
| SCHEMBL10989096 | 0.78 | KDM4E (0.68) | NLRP3KDM4ERAD52TLR8 | |
| SCHEMBL13043873 | 0.77 | NLRP3 (0.50) | NLRP3KDM4ERAD52TLR8 | |
| SCHEMBL3610430 | 0.76 | CNR2 (0.46) | CNR2KCNH2 | |
| SCHEMBL16806051 | 0.76 | CNR2 (0.46) | CNR2 | |
| SCHEMBL3622413 | 0.76 | KDM4E (0.49) | CNR2KDM4ERAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9718817-B2 | Aryl and heteroaryl ether compounds as ROR gamma modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2017-08-01 | — | — | US | disclosed |
| US-20170022195-A1 | ARYL AND HETEROARYL ETHER COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2017-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022195-A1 | ARYL AND HETEROARYL ETHER COMPOUNDS AS ROR GAMMA MODULATORS | RORB, RORA, RORC | CNR2 84/4885P2RX3 753/4885P2RX2 992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.